WaveMan
WaveMan · Company
IOBTQ · Io Biotech, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

IOBTQ IO Biotech (IOBTQ) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001865494
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

IO Biotech insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for IO Biotech, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing

no insider purchases or sales on record

0 transactions on record
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.9% of the float short (float per yahoo 2026-10-26) · 14.1 days to cover · settled 2026-09-30
below 77% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch IOBTQ

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

Who owns IOBTQ: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in IOBTQ

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

IOBTQ planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
3 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

IOBTQ financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$81.1M
operating cash flow minus capex, 2024-10-01 to 2025-09-30
Debt to equity
18.29x
long-term 2025-09-30 plus current 2025-03-31 (6 months older than the period end); equity 2025-09-30
Cash flow to debt
-4.86x
TTM operating cash flow over long-term 2025-09-30 plus current 2025-03-31 (6 months older than the period end)
Return on equity
-240.5%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on assets
-136.0%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-192.7%
operating income (EBIT proxy) over average of 2024-09-30 and 2025-09-30 minus current liabilities
P/E, trailing
n/a
no close on file at or before the as-of date
Enterprise value
n/a
no close on file at or before the as-of date
FCF yield
n/a
no close on file at or before the as-of date
PEG, trailing
n/a
no close on file at or before the as-of date
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Operating income-$95.2M-$91.4M-$71.4M-$41.2M
Net income-$95.5M-$86.1M-$71.5M-$67.9M
EPS (diluted)-1.45-1.98-2.48-17.30
Operating cash flow-$82.3M-$71.7M-$59.7M-$40.6M
Cash$60.0M$143.2M$142.6M$211.5M
Long-term debt$0n/an/an/a
SEC XBRL, fiscal years, as known on 2026-10-27

IOBTQ Stock Sonar score 3/7 axes

Find similar shapesCompare

IOBTQ ranks highest on risk and compliance (81st percentile) and financial health (15th), and lowest on profitability (14th), among Pharma & Biotech peers.

Profitability
14
Inputs
  • Return on equity-240.5% · 14 pct, sector of 545
  • Return on assets-136.0% · 17 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-192.7% · 11 pct, sector of 576
Financial health
15
Inputs
  • Debt to equity18.29x · 1 pct, sector of 352
  • Cash flow to debt-4.86x · 29 pct, sector of 371
Risk and compliance
81
Inputs
  • Short interest, % of float+0.9% · 81 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Growth, Insider conviction, Institutional and government, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies